>>Signaling Pathways>> Vitamin D Related>> VD/VDR>>Tacalcitol monohydrate

Tacalcitol monohydrate (Synonyms: Bonalfa, Curatoderm, 1α,24(R)Dihydroxycholecalciferol, PRI 2191, Tacalcitol, TV 02)

Catalog No.GC37714

타칼시톨 일수화물(1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3)은 칼슘을 조절하여 정상적인 뼈 발달을 촉진합니다.

Products are for research use only. Not for human use. We do not sell to patients.

Tacalcitol monohydrate Chemical Structure

Cas No.: 93129-94-3

Size 가격 재고 수량
1mg
US$266.00
재고 있음
5mg
US$854.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Tacalcitol monohydrate (1,24(R)-Dihydroxyvitamin D3; 1.alpha.,24R-Dihydroxyvitamin D3) promotes normal bone development by regulating calcium.IC50 value:Target: Tacalcitol modulates immunological and inflammatory processes. Tacalcitol induces nerve growth factor production in epidermal keratinocytes.

[1]. Koyano K, Saitoh Y, Oshida J, Takimoto-Kamimura M.Dimer and superstructure of the active form of a vitamin D3; 1 alpha,24(R)dihydroxy-vitamin D3 monohydrate, C27O3H44.H2O.Chem Pharm Bull (Tokyo). 2001 Mar;49(3):305-11. [2]. Fukuoka et alTacalcitol, an active vitamin D3, induces nerve growth factor in human epidermal keratinocytes. Skin Pharmacol.Appl.Skin Physiol. (2001) 14 226. [3]. Rostowska-Nadolska et al Vitamin D derivatives: calcitriol and tacalcitol inhibits interleukin-6 and interleukin-8 expression in human nasal polyp fibroblasts. Adv.Med.Sci. (2010) 55 86.

리뷰

Review for Tacalcitol monohydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 5 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tacalcitol monohydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.